

OFFICE OF THE DEAN & PRINCIPAL FAKIR MOHAN MEDICAL COLLEGE & HOSPITAL, BALASORE



(Formerly known as Government Medical College & Hospital, Balasore)
At/Po/Dist.- Balasore, Pin- 756019 (Odisha)

E-mail: dean.fmmchb@gmail.com , Tel 06782 — 224901, Fax: 06782 — 224901

No. 139

135 /D/FMMCHB

Date: 10.01.23

NOTICE

The Institutional Ethics Committee meeting shall be held on the month of February-2023. Research Proposals are invited from interested Students, Residents and Faculty members to be submitted in the office of the undersigned by 4 P.M. of 04.02.2023. Late submission of research proposals shall not be accepted. The IEC form is available in the website (www.blsmch.nic.in).

Dean & Principal,

Fakir Mohan Medical College & Hospital, Balasore.

Memo No. 136 /D/FMMCHB

Date: 10.01-23

Copy forwarded to the Chairperson, Institutional Ethics Committee, FMMCH, Balasore for information.

Copy forwarded to all the members of Institutional Ethics Committee, FMMCH, Balasore for information & necessary action.

Dean & Principal,

Fakir Mohan Medical College & Hospital, Balasore.

Memo No. 137 /D/FMMCHB

Mospital Bal Date: 10-01-23

Copy forwarded to the Superintendent/ All HODs, FMMCH, Balasore for information & necessary action.

Dean & Principal,

Fakir Mohan Medical College & Hospital, Balasore.

Dean & Principal

*akir Mohan Medical College

& Hospital, Balasore.

Institutional Ethics Committee, Fakir Mohan Medical College & Hospital, Balasore

Model form to be filled by the Principal Investigator (PI) for Submission to Institutional Ethics Committee (IEC)

(Prepared with reference to ICMR Format)

Proposal	Tit	e:
----------	-----	----

	Name, Designation	Address	Signature	
	&	Tel & Fax Nos.		
	Qualifications	E mail ID		
PI				
Co-PI/				
Collaborator				
1.				
2.				
3.				
Please attach detailed	curriculum Vita of all	investigators (With sub	ject specific publications	
to previous 5 years)				
Tiels annuanuietals				
Tick appropriately				
Consumer lands and attitude				
Sponsor Information:				
1. Indian a) Government Central State Institutional				
b) Private				
2. International Go	vernment P	rivate Oth	ners	
3. Industry Na	tional N	Aultinational		
•				
Contact address of the	e sponsor:			
Total Budget:				
Total baaget.				

1. Type of Study:	Clinical Behavioral	Epidemiological			
	Other				
			Specify		
Whether:	Multicentric				
	Single Center				
2. Status of Review:	New		Revised		
3. Clinical Trials:					
Drug/ vaccines,	/Device/ Herbal Rer	nedie:	S:		
i. Does the study in	volve use of:				
,	Drug		Devices	Vaccines	
Indian Systems o	f Medicine		Any Other	NA	
Alternate System	of Medicine				
ii. Is it approved ar	nd marketed				
In India & Europe USA					
Other countries, Specify					
iii. Does it involve a	Change in use, dos	sage, r	oute of	Yes	No
administration?					
If was NA/bathan F		4 ماريم		Vac	N.o.
If yes, Whether DGCI's/ Any other Regulatory authority's		Yes	No		
permission is obtained?					
If yes, Date of Pe	ermission:				
iv. Is it an investigational New Drug?		Yes	No		
If yes, IND No:					
a) Investigational	Brochure Submitte	d			
b) In vitro studies					
c) Preclinical Stud	ies done				
d) Clinical Study is: Phase I Phase II Phase III Phase IV					
e) Are you aware	if this study/similar			Yes	No
study is being d	one elsewhere?				
If yes, attach de	tails				

	•	•		
4. Brief description of the proposal- Introduction, review of literature, aim(s) &				
objectives justification for study, methodolo	gy describing t	he pote	ential risks & I	oenefits,
outcome measures, statistical analysis & wh	ether it is of na	ational	significance w	/ith
rationale (attach sheet with maximum 500 v	words)			
5. Subject selection:				
i. Number of subjects				
ii. Duration of study				
iii. Will subjects from both sexes be	e recruited:	Ye	s l	Vo
iv. Inclusion/ Exclusion criteria give	en:	Ye	s I	Vo
v. Type of subjects:	Volunteer		Patient	s
vi. Vulnerable subjects	Yes	No		
(Tick the approp	riate boxes)			
Pregnant Women	Children		Iderly	
Fetus	Illiterate		Handicappe	ed 🗍
Terminally ill	Seriously ill	M	entally Challe	nged
Economically &				
Socially backward	Any other			
Special group subjects	Yes		No	
(Tick the appropriate boxes)				
Captives Institu	ıtionalized	☐ Er	mployees	
Students Nurse	s/Dependent		Armed forces	
Any other Staff				
6. Privacy and Confidentiality				
i. Study involves- Direct identifiers				
In	direct identifie	rs/Code	ed	
Completely anonymised/ delinked				
ii. Confidential handling of data	by staff		Yes	No
7. Use of biological/hazardous materials			Yes	No
i. Use of fetal tissue or abortus				
ii. Use of organs or body fluids		Yes	No	
iii. Use of recombinant/gene therapy		Yes	No	
If yes, has Department of Biotechnology (DBT)				
approval for DNA products been obtained		Yes	No	
Iv. Use of pre-existing/ stored/left over samples		Yes	No	
v. Collection for banking / future research			Yes	No
vi. Use of ionizing/radioisotopes			Yes	No
if yes, Has Bhaba Atomic Research Center(BARC)				
approval for radioactive isotopes been obtained? Yes No			No	

, , , , , , , , , , , , , , , , , , ,			
vii. Use of infectious/bio-hazardous specimens	Yes	No	
viii. Proper disposal of material	Yes	No	
ix. will any sample collected from the patient be	Yes	No	
sent abroad?			
If yes, justify with details of collaborators			
a) Is the proposal being submitted for clearance	Yes	No	
from Health Minister's screening committee			
(HMSE) for International collaboration?			
b) Sample will be sent to abroad because (Tick appr	opriate box)		
Facility not available in India			
Facility in India inaccessible			
Facility available but not being accessed			
If so, Reasons			
8. Consent: *Written Oral A	udio-visual		
i. Consent form: (tick the included elements)			
Understandable language Ulternatives to pa	rticipation		
Statement that study involves research Confidentiality of	records		
Sponsor of study Contact information			
Purpose and procedure Statement that cons	ent is volunta	ry	
Risks & Discomforts Right to withdraw			
Benefits Consent for future use of Biological material			
Compensation for participation Benefits if any on future commercialization			
Compensation for study related injury (eg. Genetic basis f	_	opment)	
* If written consent is not obtained, give reason			
ii. Who will obtain consent? PI/Co-PI	Nurse/Couns	elor	
Research staff	Any other		
9. Will any advertising be done for requirement of subjects?	Yes	No	
(Posters, flyers, Brochure, websites- if so kindly attach a copy)			
10. Risk & benefits:			
i. Is the risk reasonable compared to the anticipated benefits?	Yes	No	
to subject/ community/ Country?			
ii. Is there physical/social/psychological risk/discomfit? Ye	s N	10	
If yes, Minimal or no risk			
More than minimum risk			
High Risk			
iii. Is there any benefit a) to the subject?			
Direct Indirect			
b) Benefit to society			

11. Data monitoring		Yes	No
i. Is there a data & safety monitoring committee/	Board(DSMB)		
ii. Is there a plan for reporting an adverse event?		Yes	No
If Yes, reporting is done to			
Sponsor Ethics Committee	DSMB]	
iii. Is there a plan for interim analysis of data		Yes	No
iv. Are there plans for storage & maintenance	of all trial	Yes	No
database?			
If Yes, How long?			
12. Is there compensation for participation?		Yes	No
If yes, Monetary In kind			
Specify amount & type:			
13. Is there compensation for injury?		Yes	No
If yes, by sponsor by investig			
by insurance by any ot	her		
Company			
14. Do you have conflict of interest?		Yes	No
(Financial/non-financial)			
If yes, specify			
Checklist for document attached			
D : 1 426 :			
Project proposal – 12 Copies			
Curriculum Vitae of Investigators			
Brief description of proposal			
Patient information sheet			
Informed consent form			
Investigator's brochure for recruiting subje			
Copy of advertisements/information brock	nures		
Copy of clinical trial protocol and/or			
questionnaire			
HMSC/DCGI/DBT/BARC clearance if obtain	ied		
Signature of Co DI/	Cianatura O D	:	- ef Di
Signature of Co-PI/	Signature & De	esignation	1 01 11
Collaborator			
Place:			
Date:			
Date.			